Lexicon Pharmaceuticals Statistics Share Statistics Lexicon Pharmaceuticals has 363.4M
shares outstanding. The number of shares has increased by 0.47%
in one year.
Shares Outstanding 363.4M Shares Change (YoY) 0.47% Shares Change (QoQ) 0.47% Owned by Institutions (%) 73.41% Shares Floating 183.89M Failed to Deliver (FTD) Shares 6,010 FTD / Avg. Volume 0.2%
Short Selling Information The latest short interest is 28.38M, so 7.81% of the outstanding
shares have been sold short.
Short Interest 28.38M Short % of Shares Out 7.81% Short % of Float 21.81% Short Ratio (days to cover) 15.72
Valuation Ratios The PE ratio is -1.18 and the forward
PE ratio is -4.96.
Lexicon Pharmaceuticals's PEG ratio is
0.06.
PE Ratio -1.18 Forward PE -4.96 PS Ratio 7.6 Forward PS 41.5 PB Ratio 1.62 P/FCF Ratio -1.31 PEG Ratio 0.06
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Lexicon Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.44,
with a Debt / Equity ratio of 0.74.
Current Ratio 5.44 Quick Ratio 5.44 Debt / Equity 0.74 Debt / EBITDA -0.59 Debt / FCF -0.6 Interest Coverage -12.65
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $301.76K Profits Per Employee $-1.95M Employee Count 103 Asset Turnover 0.1 Inventory Turnover 2.67
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -12.5% in the
last 52 weeks. The beta is 1.27, so Lexicon Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.27 52-Week Price Change -12.5% 50-Day Moving Average 1.14 200-Day Moving Average 0.8 Relative Strength Index (RSI) 69.78 Average Volume (20 Days) 3,061,449
Income Statement In the last 12 months, Lexicon Pharmaceuticals had revenue of 31.08M
and earned -200.4M
in profits. Earnings per share was -0.63.
Revenue 31.08M Gross Profit 30.46M Operating Income -197.12M Net Income -200.4M EBITDA -184.29M EBIT -184.82M Earnings Per Share (EPS) -0.63
Full Income Statement Balance Sheet The company has 66.66M in cash and 108.4M in
debt, giving a net cash position of -41.74M.
Cash & Cash Equivalents 66.66M Total Debt 108.4M Net Cash -41.74M Retained Earnings -1.97B Total Assets 225.58M Working Capital 110.25M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -178.78M
and capital expenditures -1.03M, giving a free cash flow of -179.81M.
Operating Cash Flow -178.78M Capital Expenditures -1.03M Free Cash Flow -179.81M FCF Per Share -0.56
Full Cash Flow Statement Margins Gross margin is 98.02%, with operating and profit margins of -634.2% and -644.78%.
Gross Margin 98.02% Operating Margin -634.2% Pretax Margin -644.78% Profit Margin -644.78% EBITDA Margin -592.93% EBIT Margin -634.2% FCF Margin -578.52%
Dividends & Yields LXRX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LXRX is $2.95,
which is 110.7% higher than the current price. The consensus rating is "Buy".
Price Target $2.95 Price Target Difference 110.7% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 21, 2015. It was a
backward
split with a ratio of 1:7.
Last Split Date May 21, 2015 Split Type backward Split Ratio 1:7
Scores Altman Z-Score -10.49 Piotroski F-Score 4
